Login to Your Account

Other News To Note

Friday, April 22, 2011
Nektar Therapeutics Inc., of San Francisco, said its oncology candidate, NKTR-102, received orphan drug status for ovarian cancer from the FDA. It is involved in an ongoing Phase II study enrolling approximately 125 patients with platinum-resistant ovarian cancer with progression following pegylated liposomal doxorubicin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription